| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Purity: ≥98%
Tavapadon (PF-6649751; CVL-751) is a partial dopamine receptor agonist with the potential to be used in the treatment of Parkinson's disease and Alzheimer's.
| Targets |
dopamine D1/D5 receptor
|
|---|---|
| ln Vivo |
Tavapadon (PF-06649751; 0.02 and 0.04 mg/kg; s.c.) has little to no effect on locomotor activity when administered at the 0.04 mg/kg test dose, in contrast to the 0.02 mg/kg dose[1].
Tavapadon (0.04 mg/kg, s.c.) also reduces parkinsonian disability scores; the greatest reduction in disability was seen 110 minutes after the drug was administered[1]. Increased Tavapadon dosages (0.1 and 0.15 mg/kg; s.c.) result in a statistically significant improvement in locomotor activity when compared to a vehicle[1]. Tavapadon (0.1 mg/kg; s.c.) in captive-bred macaques results in a mean maximal unbound plasma concentration of 8 nM three hours after compound administration[1]. |
| References |
| Molecular Formula |
C19H16F3N3O3
|
|---|---|
| Molecular Weight |
391.343854904175
|
| Exact Mass |
391.11
|
| Elemental Analysis |
C, 58.31; H, 4.12; F, 14.56; N, 10.74; O, 12.26
|
| CAS # |
1643489-24-0
|
| Related CAS # |
(Rac)-Tavapadon; 1643462-64-9
|
| Appearance |
Solid powder
|
| SMILES |
CC1=C(C=CC(=C1)OC2=C(C=CC=N2)C(F)(F)F)C3=C(C(=O)NC(=O)N3C)C
|
| InChi Key |
AKQXQLUNFKDZBN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H16F3N3O3/c1-10-9-12(28-17-14(19(20,21)22)5-4-8-23-17)6-7-13(10)15-11(2)16(26)24-18(27)25(15)3/h4-9H,1-3H3,(H,24,26,27)
|
| Chemical Name |
1,5-dimethyl-6-[2-methyl-4-[3-(trifluoromethyl)pyridin-2-yl]oxyphenyl]pyrimidine-2,4-dione
|
| Synonyms |
CVL-751; CVL 751; CVL751; PF-6649751; PF 6649751; PF6649751
|
| HS Tariff Code |
2934.99.03.00
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~255.5 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (6.39 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5553 mL | 12.7766 mL | 25.5532 mL | |
| 5 mM | 0.5111 mL | 2.5553 mL | 5.1106 mL | |
| 10 mM | 0.2555 mL | 1.2777 mL | 2.5553 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05404542 | Active Recruiting |
Drug: Tavapadon | Renal Impairment | Cerevel Therapeutics, LLC | May 10, 2022 | Phase 1 |
| NCT04542499 | Active Recruiting |
Drug: Tavapadon Drug: Placebo |
Parkinson Disease | Cerevel Therapeutics, LLC | October 27, 2020 | Phase 3 |
| NCT04201093 | Active Recruiting |
Drug: Tavapadon Drug: Placebo |
Parkinson Disease | Cerevel Therapeutics, LLC | December 13, 2019 | Phase 3 |
| NCT04223193 | Recruiting | Drug: Tavapadon Drug: Placebo |
Parkinson Disease | Cerevel Therapeutics, LLC | January 6, 2020 | Phase 3 |
| NCT04241393 | Completed | Drug: Tavapadon tablet Drug: Tavapadon [14C] suspension |
Healthy Subjects | Cerevel Therapeutics, LLC | February 4, 2020 | Phase 1 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA